AIM 101 is an injectable pharmaceutical product of aAPC nano-particles decorated with tumor-specific antigen loaded HLA molecules and antiCD28 stimulatory molecules. Based on specific size and bio-distribution characteristics, the AIM 101 aAPC have the ability to engage tumor antigen-specific T cell populations at multiple sites (Lymph Node, Lymphatic System, peripheral blood, tumor, tumor micro-environment).

Following administration in pre-clinical models, AIM 101 aAPC have demonstrated the ability to generate tumor-infiltrating lymphocytes (TILS), which are known to mediate killing in human tumors.